The BLM helicase is a new therapeutic target in multiple myeloma involved in replication stress survival and drug resistance.
Ovejero S, Viziteu E, Dutrieux L, Devin J, Lin YL, Alaterre E, Jourdan M, Basbous J, Requirand G, Robert N, de Boussac H, Seckinger A, Hose D, Vincent L, Herbaux C, Constantinou A, Pasero P, Moreaux J.
Ovejero S, et al. Among authors: devin j.
Front Immunol. 2022 Dec 9;13:983181. doi: 10.3389/fimmu.2022.983181. eCollection 2022.
Front Immunol. 2022.
PMID: 36569948
Free PMC article.